Context Therapeutics (CNTX) Competitors $1.10 +0.10 (+10.03%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.08 -0.02 (-1.82%) As of 10/3/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. TKNO, CAPR, REPL, CGC, ALEC, MREO, UPXI, CADL, ALDX, and SCPHShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Alpha Teknova (TKNO), Capricor Therapeutics (CAPR), Replimune Group (REPL), Canopy Growth (CGC), Alector (ALEC), Mereo BioPharma Group (MREO), Upexi (UPXI), Candel Therapeutics (CADL), Aldeyra Therapeutics (ALDX), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors Alpha Teknova Capricor Therapeutics Replimune Group Canopy Growth Alector Mereo BioPharma Group Upexi Candel Therapeutics Aldeyra Therapeutics scPharmaceuticals Context Therapeutics (NASDAQ:CNTX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Do analysts prefer CNTX or TKNO? Context Therapeutics presently has a consensus price target of $5.20, indicating a potential upside of 372.73%. Alpha Teknova has a consensus price target of $10.00, indicating a potential upside of 77.30%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Alpha Teknova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Alpha Teknova 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media refer more to CNTX or TKNO? In the previous week, Context Therapeutics had 4 more articles in the media than Alpha Teknova. MarketBeat recorded 4 mentions for Context Therapeutics and 0 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.00 beat Context Therapeutics' score of -0.11 indicating that Alpha Teknova is being referred to more favorably in the news media. Company Overall Sentiment Context Therapeutics Neutral Alpha Teknova Neutral Is CNTX or TKNO more profitable? Context Therapeutics has a net margin of 0.00% compared to Alpha Teknova's net margin of -55.24%. Alpha Teknova's return on equity of -26.51% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -38.80% -37.53% Alpha Teknova -55.24%-26.51%-18.40% Do insiders and institutionals have more ownership in CNTX or TKNO? 14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 2.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, CNTX or TKNO? Context Therapeutics has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$26.73M-$0.36-3.06Alpha Teknova$37.74M8.00-$26.75M-$0.42-13.43 Which has more risk and volatility, CNTX or TKNO? Context Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. SummaryContext Therapeutics beats Alpha Teknova on 10 of the 15 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.68M$2.66B$6.08B$10.56BDividend YieldN/A56.44%5.68%4.70%P/E Ratio-3.0624.2278.0526.71Price / SalesN/A590.33577.14179.08Price / CashN/A172.4737.7961.25Price / Book0.875.3412.556.56Net Income-$26.73M$32.92M$3.31B$277.70M7 Day Performance20.88%3.90%4.28%2.41%1 Month Performance32.83%10.60%7.85%9.30%1 Year Performance-42.71%-3.95%71.37%31.22% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.202 of 5 stars$1.10+10.0%$5.20+372.7%-44.4%$89.68MN/A-3.067News CoverageAnalyst ForecastGap UpHigh Trading VolumeTKNOAlpha Teknova1.5011 of 5 stars$5.65-6.9%$10.00+77.0%+11.5%$324.84M$37.74M-13.45240CAPRCapricor Therapeutics2.6021 of 5 stars$7.41+4.5%$22.25+200.3%-56.9%$324.13M$22.27M-4.52101REPLReplimune Group4.7366 of 5 stars$4.34+5.1%$6.50+49.8%-59.5%$322.37MN/A-1.34210CGCCanopy Growth0.8708 of 5 stars$1.57+17.2%N/A-70.1%$321.40M$225.65M-0.523,150High Trading VolumeALECAlector3.7739 of 5 stars$3.05-1.6%$4.17+36.6%-21.3%$313.76M$100.56M-2.63270Analyst RevisionMREOMereo BioPharma Group2.656 of 5 stars$1.96+1.0%$7.40+277.6%-53.6%$308.46M$10M-28.0040News CoveragePositive NewsUPXIUpexi2.4847 of 5 stars$5.62+7.7%$15.50+175.8%N/A$307.11M$15.81M0.00130Short Interest ↑Gap DownCADLCandel Therapeutics2.5846 of 5 stars$5.40-2.5%$20.00+270.4%-17.1%$304.12MN/A-7.8360ALDXAldeyra Therapeutics2.3005 of 5 stars$5.21+2.8%$9.50+82.3%+9.8%$303.67MN/A-6.1310News CoverageSCPHscPharmaceuticals4.2206 of 5 stars$5.67+0.4%$7.78+37.3%+30.6%$301.14M$36.33M-3.1330Positive News Related Companies and Tools Related Companies TKNO Alternatives CAPR Alternatives REPL Alternatives CGC Alternatives ALEC Alternatives MREO Alternatives UPXI Alternatives CADL Alternatives ALDX Alternatives SCPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTX Stock Alerts